Aspirin Delimits Platelet Life Span by Proteasomal Inhibition

Manasa K. Nayak¹*, Ayusman Dash², Nitesh Singh¹, Debabrata Dash¹*

¹ Department of Biochemistry, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India, ²Indian Institute of Science Education and Research, Kolkata, India

Abstract

Aspirin is widely used in clinical settings as an anti-inflammatory and anti-platelet drug due its inhibitory effect on cyclooxygenase activity. Although the drug has long been considered to be an effective and safe therapeutic regime against inflammatory and cardiovascular disorders, consequences of its cyclooxygenase-independent attributes on platelets, the key players in thrombogenesis, beg serious investigation. In this report we explored the effect of aspirin on platelet lifespan in murine model and its possible cytotoxicity against human platelets in vitro. Aspirin administration in mice led to significant reduction in half-life of circulating platelets, indicative of enhanced rate of platelet clearance. Aspirin-treated human platelets were found to be phagocytosed more efficiently by macrophages, associated with attenuation in platelet proteasomal activity and upregulation of conformationally active Bax, which were consistent with enhanced platelet apoptosis. Although the dosage of aspirin administered in mice was higher than the therapeutic regime against cardiovascular events, it is comparable with the recommended anti-inflammatory prescription. Thus, above observations provide cautionary framework to critically re-evaluate prophylactic and therapeutic dosage regime of aspirin in systemic inflammatory as well as cardiovascular ailments.

Introduction

Although aspirin has been widely used therapeutically against variety of inflammatory conditions since 1890s [1], its anti-platelet activity was not documented until almost 70 years later [2]. The central role of platelets in pathogenesis of occlusive coronary and cerebral thrombotic events has prompted in-depth investigations into molecular underpinnings of aspirin action. Platelets generate thromboxane A2 (TXA2) in response to diverse physiological stimuli like collagen, thrombin and ADP that cause amplification of platelet aggregation and vasoconstriction [3,4]. Aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) effectively attenuate activity of the enzyme cyclooxygenase-1 (COX-1), which catalyzes biosynthesis of cyclic prostanoids like TXA2, prostacyclin and other prostaglandins (PG) [5]. Although this accounts for strong anti-thrombotic potential of aspirin, inhibition of prostaglandin synthesis, too, results in altered functions of normally protective prostaglandins with potentially serious consequences. Aspirin-induced inhibition of COX results in loss of cytotoxic effects of PGE2 on gastric mucosa, which partly accounts for gastrointestinal side effects associated with aspirin therapy [5–8], especially during high dosage of aspirin administered for treatment of systemic inflammatory ailments including rheumatoid arthritis [9].

Aspirin also elicits effects that are independent of COX inhibition [10–17]. Prolonged use of NSAIDs has been reported to reduce the risk of malignancies, though their anti-cancer activity has not been fully established [18–22]. Aspirin induces shedding of GPIIb/IIIa and GPV from platelet surface through activation of the metalloproteinase ADAM17 and cell death [23,24]. Clinical trials have indicated that chemopreventive properties of NSAIDs could be due to induction of apoptosis [6–8]. Several mechanisms have been proposed to explain aspirin-induced apoptosis, which include upregulation of pro-apoptotic proteins [7,8,25,26] and oxidative stress [27,28]. Aspirin has been shown to induce decrement in mitochondrial transmembrane potential and stimulate intrinsic pathway of apoptosis in mouse Neuro 2a cells [29]. There have been few clinical studies to suggest decrease in platelet count in individuals under aspirin medication [30–32]. Although aspirin has long been considered to be an effective and safe therapeutic regime against cardiovascular disorders, consequences of its pro-apoptotic attributes on platelets, the key players in thrombogenesis, demand serious investigation.

Proteasome, the protein degradation machinery of the cell, cleaves intracellular proteins in order to regulate essential cellular processes like antigen processing, cell cycle, transcription and signal transduction [33–36]. We have recently demonstrated a central role of proteasome in determination of platelet life span [37] and the factors regulating its enzymatic activity in human
platelets [38]. In the present study, we have evaluated effect of aspirin on platelet survival in murine as well as human models. Aspirin induced apoptosis in human platelets in a dose-dependent manner, which was associated with concomitant inhibition of platelet proteasomal activity in presence of the drug. Platelet half life was found to be significantly lowered in aspirin-treated mice as compared to control animals. Thus, above observations provide cautionary framework to critically re-evaluate prophylactic and therapeutic dosage regime of aspirin in clinical practice. Despite widespread use of aspirin against cardiovascular ailments, its preventive administration in susceptible individuals on routine basis is not recommended [39–41]. Aspirin has been reported to be safe for primary prevention at coronary event risk >1.5%/year though it is not recommended due to associated side effects at coronary event risk 0.5%/year [42]. In standard doses (325 mg) aspirin poses less threat of gastrointestinal bleeding; however, the bleeding risk is still twice as high as without aspirin [43].

Ethics Statement
The animal study was approved by the Central Animal Ethical Committee of Institute of Medical Sciences, Banaras Hindu University, Varanasi, Swiss Albino mice weighing between 18 and 20 gm (20 control and 40 aspirin-treated) were used in the entire study. All efforts were made to minimize the number of animals used and their suffering.

Materials and Methods
ABT-737 was purchased from Selleck Chemicals. Anti-CD61 PE and annexin V-PE were from BD Pharmingen. Proteasome inhibitor PSI [Z-Ile-Glu(OtBu)-Ala-Leu-CHO] procured from Calbiochem. N-hydroxyssuccinimidobiotin (NHS-biotin), PE-streptavidin, 5,5'-6,6'-tetrachloro-1',3',3'' tetrathylbenzimidazolylcarbonyl cyanine iodide (JC-1), thiazole orange, carbonyl cyanide 3-chlorophenylhydrazone (CCCP), 6-carboxy-2',7'-dichlorohydrinthiophosforylasecin (H2DCFDA), acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (AC-DEVD-AMC), apyrase, ethylene glycol tetra acetic acid (EGTA), ethylene diamine tetra acetic acid (EDTA), sodium orthovandate, acetylalivacylic acid (aspirin), bovine serum albumin (fraction V), Triton X-100, protease inhibitors, mouse monoclonal anti-Bax (6A7) were purchased from Sigma. RPMI 1640 was purchased from HiMedia. Reagents for electrophoresis were products of Merck. PVDF membranes were from Millipore. SuperSignal West Pico chemiluminescent substrate was from Pierce. Horseradish peroxidase (HRP)-labeled secondary antibodies were purchased from Transduction Laboratories and Bangalore Genei, respectively. All other reagents were of analytical grade. Type 1 deionized water (18.2 MΩ cm, Millipore) was used for preparation of solutions.

Platelet preparation
Platelets were isolated from fresh human blood by differential centrifugation, as already described [44]. Briefly, blood was collected from healthy volunteers (majority male) under informed consent and centrifuged at 180 x g for 10 min. PRP (platelet-rich plasma) thus obtained was incubated with 1 mM acetylsalicylic acid for 15 min at 37°C. After addition of EDTA (ethylenediaminetetraacetic acid) (5 mM), platelets were sedimented by centrifugation at 800 x g for 15 min. Cells were washed in buffer A (20 mM HEPES, 138 mM NaCl, 2.9 mM KCl, 1 mM MgCl2, 0.36 mM Na2HPO4, 1 mM EDTA (ethylene glycol tetraacetic acid), supplemented with 5 mM glucose and 0.6 ADPase units of apyrase/ml, pH 6.2) and were finally resuspended in buffer B (20 mM HEPES, 138 mM NaCl, 2.9 mM KCl, 1 mM MgCl2, 0.36 mM Na2HPO4, pH 7.4). The final cell count was adjusted to 0.5 – 0.8x10^9/ml. All steps were carried out under sterile conditions and precautions were taken to maintain the cells in resting condition.

Proteasome activity assay
Platelets were incubated at 37°C for 30 min with aspirin (2, 5 and 10 mM) or vehicle (ethanol) and washed twice in buffer A (see above). Cells were pelleted and resuspended in 125 μl of 2x permeabilization buffer (20 mM HEPES, 0.2% Triton X-100, 300 mM NaCl and 2 mM EGTA, pH 7.7) followed by addition of 125 μl of 2x proteasome assay buffer (40 mM HEPES, 1 mM EDTA and 0.07% SDS, pH 7.8). Permeabilized cells were added to the wells of microplates in a fluorescence microplate reader (BioTek model FLx800) at 37°C. Reaction was started by the addition of Suc-Leu-Leu-Val-Tyr-AMC (25 μM) in DMSO and was monitored for 10 min (excitation, 360 nm; emission, 460 nm) [37]. Proteasome peptidase activities were determined from Suc-LLVY-AMC-hydrolyzing activity (chymotrypsin-like activity).

Cytofluorimetric analysis of mitochondrial transmembrane potential
Mitochondrial transmembrane potential (ΔΨ) was measured using the potential-sensitive fluorochrome JC-1, which selectively moves across polarized mitochondrial membrane and forms aggregates (red). As membrane potential collapses, color changes from red to green due to release of monomeric dye [37]. In order to study ΔΨ, platelets were pre-treated with aspirin (2, 5 and 10 mM) or ethanol (vehicle) for 30 min, followed by incubation with 2 μM JC-1 for 15 min at 37°C in dark. Cells were washed in phosphate-buffered saline (PBS) and JC-1 fluorescence was analyzed in FL1 and FL2 channels of flow cytometer (FACSCalibur, Becton Dickinson) for detection of dye monomers and aggregates, respectively. The ratio of red to green (FL2/FL1) fluorescence reflected mitochondrial transmembrane potential.

Flow cytometric measurement of reactive oxygen species (ROS)
Platelets were treated with aspirin (2, 5 and 10 mM) or ethanol (vehicle) as above, washed with PBS and incubated with H2DCFDA (1 μM) for 30 min at 37°C in dark. Cells were next washed twice with PBS and analyzed by flow cytometry as described previously [45].

Measurement of annexin v and P-selectin binding by flow cytometry
Platelets (1x10^9 cells in 100 μl) were incubated at 37°C for 30 min in the presence aspirin or vehicle as stated above. For positive control the washed platelets were treated with thrombin (1 U/ml) for 10 min without stirring. Then equal amount of 4% paraformaldehyde was added to the cells and incubated for 30 min, which was followed by washing. Post-fixed resuspended platelets were labeled with 5 μl FITC-labeled P-selectin antibody, 5 μl PE-labeled annexin V (in presence of 5 mM CaCl2 to promote binding). Samples were incubated for 30 min at RT in dark and analyzed on the flow cytometer [45]. After compensation between FITC and PE, all fluorescence data were collected using four-quadrant logarithmic amplification. Data from CD61-positive 10,000 events were collected for each sample.

Caspase-3 activity assay
To determine cytosolic caspase-3 activity, samples were pre-treated with 2, 5 and 10 mM of aspirin or vehicle (ethanol) and
lysed with equal amount of 2× RIPA buffer. After 10 min incubation in ice, equal volume of 2× substrate buffer (20 mM HEPES, pH 7.4, 2 mM EDTA, 0.1% CHAPS, 5 mM DTT and 10 μM caspase substrate AC-DEVD-AMC) was added to each lysate and further incubated for 30 min at 37°C [43]. Caspase-3 activity was determined from the extent of cleavage of fluorogenic substrate measured at 460 nm emission (excitation, 360 nm).

**Western blotting**

Proteins were separated by 13% SDS-PAGE and electrophoretically transferred onto PVDF membrane (0.8 mA/cm², 2 h) in a semi-dry blotter (TE 77 PVR, GE Healthcare) for subsequent probing as described previously [37]. Blots were incubated for 1 h with 5% (w/v) BSA in Tris-buffered saline containing 0.05% Tween 20 (TBST) to block residual protein binding sites. Membranes were incubated overnight at 4°C with the primary antibody (anti-Bax, 1:500). Blots were incubated with the appropriate HRP-conjugated secondary antibody (diluted 1:10,000) and exposed to enhanced chemiluminescence reagents for 5 min. Blots were exposed to photographic films and densitometrically scanned. For protein loading control, membranes containing whole cell lysates were reprobed with the anti-actin antibody (1:1000).

**Platelet clearance analysis**

Mice were orally administered with aspirin (10 and 15 mg/kg/day, respectively, in two groups) for 4 days. The control animals were administered with vehicle. In different experiments mice were intravenously injected with 50 and 75 mg/kg of aspirin. NHS-biotin (600 mg) was injected in tail vein of either ethanol (control) or aspirin administered mice [46]. At various time points 50 μl retro-orbital blood was drawn from both control as well as treated mice, mixed with 200 μl buffered saline-glucose-citrate buffer (116 mM NaCl, 13.6 mM trisodium citrate, 8.6 mM Na2HPO4, 1.6 mM KH2PO4, 0.9 mM EDTA, 11.1 mM glucose) and followed by 1 ml balanced salt solution (149 mM NaCl, 3.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 7.4 mM HEPES, 1.2 mM KH2PO4, 0.85 mM K2HPO4, 3% bovine calf serum). Cells were pelleted at 1400 g for 10 min, and resuspended in 300 μl sheath fluid. They were stained with FITC-conjugated rat anti-CD41, which label only platelets, followed by PE-streptavidin for 1 h on ice, washed in balanced salt solution and analyzed by flow cytometry to determine the fraction of platelet population labeled with PE.

**Monocyte isolation, culture and phagocytic recognition of platelets**

Human monocytes were isolated and cultured as described [47,48]. Briefly, blood from healthy donors was collected in citrate and peripheral blood mononuclear cells (PBMCs) were isolated using Hysep, according to manufacturer’s instructions. Monocytes were further isolated by plating the PBMCs on polysytrene-coated tissue culture flasks for 4 h at 37°C, followed by 3 washes with PBS to remove non-adherent lymphocytes. Monocytes (250,000 in 500 μl volume) were then plated on 6-well plates in RPMI 1640 supplemented with 10% fetal bovine serum and cultured for 7 days to obtain the monocyte-derived macrophages (MDMs). Platelets labeled with calcin-AM were incubated with monolayer of autologous monocyte-derived adherent human macrophages for 45 min. Following incubation period, the phagocytosis monolayer was washed free of non-interacting platelets, and any adherent platelets were removed by treatment with trypsin at 37°C for 5 min followed by 5 mM EDTA at 4°C. MDMs were recovered by trypsin/EDTA treatment for 15 min at 37°C and subjected to flow cytometric and epifluorescent microscopic analysis.

In different experiments, aspirin (10 mg/kg/day) was administered orally to mice for 7 days, following which macrophages were isolated from the peritoneal cavity of animals. Platelets were isolated from control as well as aspirin-administered mice and stained with calcin-AM. Equal number of platelets from either group was co-incubated ex vivo with respective pre-isolated macrophages for 45 min in CO2 incubator. Macrophages were gated and analyzed by flow cytometry for fluorescence signal (FL1).

**Statistical methods**

Standard statistical methods were used. Parametric methods (t test) were used for evaluation and tests were considered significant at P<0.05 (2-tailed tests). Data are presented as means ± SD of at least five individual experiments from different blood donors.

**Results**

Aspirin induces apoptosis-like phenotype in human platelets associated with upregulation of Bax and proteasomal inhibition

NSAIDs have been reported to induce apoptosis presumably independent of their ability to inhibit cyclooxygenase activity [5–8]. In order to evaluate aspirin action on platelets, we investigated mitochondrial transmembrane potential (ΔΨm) and surface exposure of phosphatidylserine (PS) in aspirin-treated human platelets. JC-1, a lipophilic cation, was employed to determine alterations in ΔΨm. As expected, high aggregate to monomer fluorescence ratio (FL2/FL1) of the fluor was observed in untreated (control) cells indicative of stabilized ΔΨm, which dropped drastically in carbonyl cyanide 3-chlorophenylhydrazone (CCCP) (protonophore) (30 μM)-treated platelets (Fig. 1A). Incubation of platelets with different concentrations of aspirin (2, 5 and 10 mM) was associated with significant decrements in ΔΨm (by 25%, 61% and 93%, respectively) as compared to control (Fig. 1A).

Externalization of PS, an anionic phospholipid, from the inner leaflet to outer layer of cell membrane is an invariable feature in the apoptotic process [37,49]. PE-annexin V binding to cell surface was studied as a measure of cells undergoing apoptosis. As expected, surface membrane was found to be significantly enriched with PS in thrombin-stimulated platelets as compared to the resting cells. Remarkably, pretreatment of platelets with increasing concentrations of aspirin (2, 5 and 10 mM) resulted in dramatic increase (by 1.69-, 7- and 11-folds, respectively) in annexin V binding as compared to the untreated (control) cells, indicative of induction of apoptosis-like changes upon aspirin treatment (Fig. 1B). Salicylic acid (10 mM) did not elicit increment in annexin V binding, which indicated that aspirin caused PS exposure by acetylation-dependent mechanism. To rule out the possibility of platelet activation in response to different dosages of aspirin, we examined surface expression of P-selectin, a marker for platelet activation, in aspirin-treated platelets. Aspirin had no effect on surface level of P-selectin, which was found to be significantly elevated on surface membrane in thrombin-stimulated platelets (Figure S1).

As apoptosis is known to be associated with cellular reactive oxygen species (ROS) generation [50], we sought to determine whether aspirin induced ROS production in platelets. Using the cell-permeable dye 2’,7’-dichlorofluorescein diacetate (H2DCFDA), intracellular ROS was found to be significantly
Figure 1. Study of apoptosis-like features in platelets following aspirin treatment. Mitochondrial transmembrane potential (red/green ratio) (A), PS exposure (PE-annexin V binding) (B) and ROS generation (C) were studied in control platelets, as well as in cells pre-treated with aspirin as indicated. In (A), CCCP (mitochondrial protonophore) has been employed as the positive control. Data are representative of five different experiments and expressed as mean±SD. (*p<0.05 as compared to ethanol-pretreated resting platelets).

doi:10.1371/journal.pone.0105049.g001
Aspirin Delimits Platelet Life Span

Aspirin leads to decreased platelet life span

Platelet life span is determined by opposing activities of anti- and pro-apoptotic Bcl-2 family proteins [46]. As proteasomal activity in tumor cells influences cellular level of these proteins and aspirin attenuated proteasome function in platelets [37]. In order to explore the effect of aspirin on proteasome in human platelets, we analyzed proteasomal peptidase activity in presence of different concentrations of aspirin. We found a concentration-dependent attenuation (by 15%, 44% and 61%) in proteasome function in human platelets pre-treated with aspirin (2, 5 and 10 mM, respectively) (Fig. 2D). Aspirin treatment did not induce any change in the total protein content in platelets.

Discussion

Aspirin is one of the most widely used medications worldwide, with more than 100 billion tablets consumed each year [53]. Aspirin is extensively used under clinical settings as an anti-inflammatory drug and for prevention of thrombus formation/propagation in myocardial infarction as well as stroke by inhibition of platelet COX-1 activity. Apart from above functions, aspirin and other NSAIDs also reportedly exhibit antiproliferative effect. In this study we have investigated apoptosis-like changes in human platelets elicited by aspirin and explored its effect on murine platelet lifespan in vivo. Here we found that, platelets exhibited features of apoptosis following aspirin treatment, which included drop in mitochondrial transmembrane potential, enhanced surface exposure of PS, rise in cytosolic ROS and activation of caspase-3. The pro-apoptotic Bcl-2 family protein Bax and Bax-specific mRNA are known to be abundantly expressed in platelets [54,55]. Aspirin treatment provoked significantly higher expression of conformationally active Bax in platelets compared to their control (untreated) counterparts. Bax being a known substrate of proteasome [56,57] we next examined effect of aspirin on proteasomal peptidase activity in order to understand mechanistic underpinning of aspirin effects on platelets. The drug was found to elicit concentration-dependent attenuation in proteasomal function in human platelets (Fig. 2D), which was in line with an earlier study on murine Neuro 2a cells [29]. However, above observations did not formally establish a link between proteasome inhibition and Bax activity. A limitation of this study is high dose of aspirin administered in mice. Although effective therapeutic dosage of aspirin against coronary artery disorders is lower than that employed in this study, drug regimen against rheumatoid arthritis [9] and other systemic inflammatory
diseases is higher by 5–10 fold, which is fairly comparable with aspirin orally administered in mice in our study. Salicylic acid (10 mM) did not evoke any apoptotic response, which indicated that effect of aspirin could be due to acetylation-dependent process.

We have recently shown that, proteasome plays critical role in platelet survival through constitutive elimination of the conformationally active Bax [37]. As aspirin inhibited proteasome activity in human platelets, we next asked whether the drug would adversely affect platelet life span in an in vivo rodent model. Administration of mice with aspirin led to thrombocytopenia. This was associated with significant reduction in half-life of circulating platelets, indicative of enhanced rate of platelet clearance in aspirin-administered mice. Consistent with this, aspirin-treated human platelets were found to be phagocytosed more efficiently by macrophages, as demonstrated in vitro by flow cytometry as well as epifluorescence microscopy.

Figure 2. Study of proteosome and caspase-3 activities in aspirin-treated platelets (A). Western blots showing expression level of active Bax in platelets pretreated with ethanol, aspirin, ABT737, epoxomicin, PSI and bortezomib, as indicated (upper panel) normalized against β-actin (lower panel). (B), Quantitative representation of active Bax levels in platelet whole cell lysates determined by densitometry of Western blots. (C), caspase-3 activity from the extent of cleavage of fluorogenic substrate AC-DEVD-AMC. (D), Assay of proteasome enzymatic activity in platelets pretreated with ethanol, PSI (proteasome inhibitor) (10 μM) and aspirin. Data are representative of five different experiments and expressed as mean±SD. (*p<0.05 as compared to ethanol-pretreated resting platelets).

doi:10.1371/journal.pone.0105049.g002
Figure 3. Aspirin affects lifespan and phagocytic uptake of platelets (A). Platelet count in control as well as aspirin-administered mice on different days. (B), Proportion of biotinylated platelets (%) in peripheral blood sample drawn from ethanol (vehicle) or aspirin (10 and 15 mg/kg) pre-administered mice 0, 24, 48, 72, and 96 h after administration of NHS-biotin. \( t_{1/2} \) (h) represents platelet half-life in hours. (C) and (D), phagocytic uptake of platelets by autologous macrophages. Flow cytometry (C) and epifluorescence microscopy (D) of macrophages co-incubated with calcein-labeled platelets pretreated either with aspirin (5 mM) or ethanol (control). Scale bars, 10 \( \mu \text{m} \). Data are representative of five different experiments.

doi:10.1371/journal.pone.0105049.g003
To summarize, we have shown that aspirin elicits apoptosis-like changes in human platelets in vitro and delimits platelet life span in murine model, which was associated with proinflammatory inhibition and increased expression of conformationally active Bax. Our observations support the contention that, platelets should not be collected under NSAID cover for the purpose of transfusion. A recent report has implicated platelets in thrombosis and towards prevention of occlusive platelet thrombi in coronary as well as cerebral thrombotic events including myocardial infarction. Therefore, observations from this study provide cautionary framework to critically re-evaluate therapeutic dosage regime of aspirin especially against systemic inflammatory ailments though it is a relatively safe drug in general clinical practice.

Supporting Information

Figure S1 Study of P-selectin exposure in aspirin treated platelets and thrombin (1 U/ml) was used as positive control.

Author Contributions

Conceived and designed the experiments: DD. Performed the experiments: MKN-AD NS. Analyzed the data: MKN DD. Wrote the paper: MKN DD.

References

1. Dreser H (1899) Pharmakologisches uber aspirin (ätherblassbäure). Pflüger's Arch 76: 306–313.
2. Weiss HJ, Aledort LM (1967) Impaired platelet-connective-tissue reaction in man after aspirin ingestion. Lancet 2: 495–497.
3. Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc. Natl. Acad. Sci. USA 72: 2294–2298.
4. Fitzgerald GA (1991) Mechanisms of platelet activation: thromboxane A2 as an amplifying signal for other agonists. Am. J. Cardiol 68: 118–15B.
5. The Swedish Cooperative Study Group (1986) High-dose acetylsalicylic acid after cerebral infarction: a Swedish cooperative study. Stroke 18: 325–334.
6. UK-TIA Study Group (1980) United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. Br. Med. J. 296: 316–320.
7. The SALT Collaborative Group (1994) Swedish aspirin low-dose trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. Lancet 338: 1134–1139.
8. Roderick PJ, Wilkes HG, Meade TW (1993) The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br. J. Clin. Pharmacol 35: 219–226.
9. Roth S, Agrawal N, Mahowald M, Montoya H, Robbins D, et al. (1989) Misoprostol heals gastrointestinal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med 149: 773–779.
10. Shiff SJ, Qiao L, Tsai LL, Rigas B (1995) Sulindac sulfide, an aspirin-like anti-inflammatory drug-induced apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. USA 102: 17207–17212.
11. Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR (2006) Aspirin induces apoptosis through the inhibition of proteasome function. J. Biol. Chem 281: 29226–29235.
12. Shiff SJ, Qiao L, Rigas B (1996) Nonsteroidal antiinflammatory drugs inhibit the proliferation of colon cancer cell lines: effect on cell cycle and apoptosis. Exp. Cell Res 222: 179–181.
13. Zimmermann KC, Waterhouse NJ, Goldstein JC, Schuler M, Green DR (2000) Aspirin induces apoptosis through release of cytochrome c from mitochondria. Pfluger's Arch 450: 505–513.
14. Zhou XM, Wong BCY, Fan XM, Zhang HB, Lin MCM, et al. (2001) Nonsteroidal anti-inflammatory drugs induced apoptosis in gastric cancer cells through upregulation. Carcinogenesis 22: 1393–1397.
15. Pique M, Barragan M, Dalmau M, Bellosillo B, Pons G, et al. (2000) Aspirin induces apoptosis through release of cytochrome c from mitochondria. FEBS Lett 480: 193–196.
16. Bellosillo B, Pique M, Barragan M, Castano E, Villarroya N, et al. (1998) Aspirin and salicylate induce apoptosis and activation of caspases in B-chronic lymphocytic leukemia cells. Blood 92: 1406–1414.
17. Go Q, Wang JD, Xia HH, Lin MCM, He H, et al. (2005) Activation of the caspase-8/9/Bid and Bax pathways in aspirin-induced apoptosis in gastric cancer. Carcinogenesis 26: 541–546.
18. Gupta RA, DuBois RN (1998) Aspirin, NSAIDs, and colon cancer prevention: shield or blade? Gastroenterology 114: 1095–1096.
19. Rao CV, Reddy BS (2004) NSAIDs and Chemoprevention. Curr. Cancer Drug Targets 4: 29–42.
20. Thun MJ, Henley SJ, Patrano C (2002) Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanism, pharmacologic, and clinical issues. J. Natl. Cancer Inst 94: 252–260.
21. Greenberg ER, Baron JA, Freeman DH, Mandel JS, Hale R (1993) Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J. Natl. Cancer Inst 85: 912–916.
22. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, et al. (1995) Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med. 333: 609–614.
23. Akras B, Pozajzova M, Bergmeier W, Sumarborg S, Offermans S, et al. (2005) Aspirin induces platelet receptor shedding via ADAM17 (TACE). J. Biol. Chem 280: 39716–39722.
24. Zhao L, Zhang W, Chen M, Zhang J, Zhang M, et al. (2013) Aspirin Induces platelet apoptosis. Platelets 24: 657–642.
25. Zhang L, Yu J, Park BH, Kinder KW, Vogelstein B (2000) Role of Bax in the apoptotic response to anti-estrogen agents. Science 290: 989–992.
26. Ho CC, Yang XW, Lee TL, Liao PH, Yang SH, et al. (2003) Activation of p53 signaling in acetylsalicylic acid-induced apoptosis in OC2 human oral cancer cells. Eur. J. Clin.Investig 33: 875–882.
27. Tsutsumi S, Gotoh T, Tomisato W, Minna S, Hoshino T, et al. (2004) Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death Differ 11: 1009–1016.
28. Gao J, Liu X, Rigas B (2005) Nitrice-oxidation aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. Proc. Natl. Acad. Sci. USA 102: 17207–17212.
29. diSipio P, Chatterjee M, Goswami A, Mishra A, Jana NR (2006) Aspirin induces apoptosis through the inhibition of proteasome function. J. Biol. Chem 281: 29226–29235.
30. Eckert MA, Kaya E, Berber I, Koroglu M, Kuka I (2012) Thrombocytopenia in Adults: Review Article. J. Hematol 1: 44–53.
31. Hu Y, Yuan M, Lu X (2013) Thrombocytopenia induced by both aspirin and clopidogrel in the same patient. Int. J. Clin. Pharmacol. Ther 51: 228–231.
32. eHealthMe (2014) Could aspirin cause platelet count decrease? Available:
33. Arendt CS, Hochstrasser M (1997) Identification of the yeast 20S proteasome catalytic centers and subunit interactions required for active-site formation. Proc. Natl. Acad. Sci. USA 72: 2294–2298.
34. Rosenzweig R, Glickman MH (2000) Chaperone-driven proteasome assembly. Biochem. Soc. Trans 23: 807–812.
35. Ferrell K, Wilkinson CR, Duhrel W, Gordon C (2000) Regulatory subunit interactions of the 26S proteasome, a complex problem. Trends Biochem. Sci. 25: 83–93.
36. Glickman MH (2000) Getting in and out of the proteasome. Semin. Cell Dev. Biol 11: 149–158.
37. Nayak MK, Kulkarni PP, Dash D (2012) Regulatory role of proteasome in apoptosis. J. Hematol 1: 44–53.
38. Nayak MK, Kulkarni PP, Dash D (2012) Regulation of proteasome activity in activated human platelets. Cell Calcium 49: 226–232.
39. Algra A, Greving JF (2009) Aspirin in primary prevention: sex and baseline risk marker. Lancet 373: 1821–2.
40. Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, et al. (2010) Aspirin for Primary Prevention of Cardiovascular Events in People With Diabetes. Diabetes Care 33: 1045–1042.
41. Medicines and Healthcare Products Regulatory Agency, Commission on Human Medicines (2009) Aspirin: not licensed for primary prevention of thrombotic vascular disease. Drug Safety Update 3: 5.
42. Sammunaganathan PS, Ghahramani P, Jackson PR, Walls EJ, Ramsay LE (2001). Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85: 265–271.
43. Park KI, Bavry AA (2013). Aspirin: Its risks, benefits, and optimal use in preventing cardiovascular events. Cleveland Clinic Journal of Medicine 80: 318–320.
44. Nayak MK, Singh SK, Roy A, Prakash V, Kumar A, et al. (2011) Anti-thrombotic effects of selective estrogen receptor modulator tamoxifen. Thromb. Haemost. 105: 624–635.
45. Lopez JJ, Salido GM, mez-Artega EG, Rosado JA, Pariente JA, et al. (2007) Thrombocytopenia through release of cytochrome c from mitochondria. Pfluger's Arch 450: 505–513.
46. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, et al. (2007) Programmed anuclear cell death delimits platelet life span. Cell 128: 1173–1186.
47. Kodama T, Takehara T, Hikita H, Shimizu S, Shiogakawa M, et al. (2011) BH3-only activator proteins Bid and Bim are dispensable for Bak/Bax-dependent thrombocyte apoptosis induced by Bcl-xL deficiency: molecular requisites for the mitochondrial pathway to apoptosis in platelets. J. Biol. Chem 286: 13095–130913.
48. Brown SB, Clarke MG, Magowan L, Sanderson H, Savill J, et al. (2000) Constitutive death of platelets leading to scavenger receptor mediated phagocytosis. A caspase-independent cell clearance program. J. Biol. Chem 275: 5987–5996.
49. Leytin V, Allen DJ, Mutlu A, Gyulkhandanyan AV, Mykhaylov S, et al. (2009) Mitochondrial control of platelet apoptosis: effect of cyclosporin A, an inhibitor of the mitochondrial permeability transition pore. Lab Invest 89: 374–384.
50. Circu ML, Aw TY (2010) Reactive oxygen species, cellular redox systems, and apoptosis. Free Radic. Biol. Med 48: 749–62.
51. Er E, Oliver L, Cartron PF, Juin P, Manon S, et al. (2006) Mitochondria as the target of the pro-apoptotic protein Bax. Biochim. Biophys. Acta 1757: 1301–1311.
52. Pereira J, Palomo I, Ocqueteau M, Soto M, Aranda E, et al. (1999) Platelet aging in vivo is associated with loss of membrane phospholipid asymmetry. Thromb. Haemost 82: 1318–1321.
53. Warner TD, Mitchell JA (2002) Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum? Proc. Natl. Acad. Sci. USA 99: 13371–13373.
54. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, et al. (2007) Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14: 943–951.
55. Vaynag DM, Orrenius S, Aguilar-Santelises M (1997) Alterations in Bcl-2/Bax protein levels in platelets form part of an ionomycin-induced process that resembles apoptosis. Br. J. Haematol 99: 824–831.
56. Fu NY, Sukumaran SK, Kerk SY, Yu VC (2009) Bax: A constitutively active human Bax isoform that is under tight regulatory control by the proteasomal degradation mechanism. Molecular Cell 33: 15–29.
57. Li B, Dou QP (2000) Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. Proc. Natl. Acad. Sci. USA 97: 3851–3855.
58. Cho MS, Botsford-Miller J, Vasquez HG, Stone R, Zand B, et al. (2012) Platelets increase the proliferation of ovarian cancer cells. Blood 120: 4869–4872.
59. Rothwell PM, Price JF, Fovskes FGR, Zanchetti A, Roncaglioni MC, et al. (2012) Short-term effects of daily aspirin on cancer incidence, mortality, and non-vascular death: analysis of the time course of risks and benefits in 51 randomised controlled trials. Lancet 379: 1602–1612.